Helicobacter pylori vaccine

From past to future

Kanishtha Agarwal, Shvetank Agarwal

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma (MALToma), and gastric adenocarcinoma. Infection is usually acquired during childhood and tends to persist unless treated. Because eradication requires treatment with multidrug regimens, prevention of initial infection by a suitable vaccine is attractive. Although immunization with H pylori protein subunits has been encouraging in animals, similar vaccine trials in humans have shown adjuvant-related adverse effects and only moderate effectiveness. Newer immunization approaches (use of DNA, live vectors, bacterial ghosts, and microspheres) are being developed. Several questions about when and whom to vaccinate will need to be appropriately answered, and a cost-effective vaccine production and delivery strategy will have to be useful for developing countries. For this review, we searched MEDLINE using the Medical Subject Heading (MeSH) terms Helicobacter pylori and vaccines for articles in English from 1990 to 2007.

Original languageEnglish (US)
Pages (from-to)169-175
Number of pages7
JournalMayo Clinic Proceedings
Volume83
Issue number2
DOIs
StatePublished - Jan 1 2008

Fingerprint

Helicobacter pylori
Vaccines
Immunization
Medical Subject Headings
Marginal Zone B-Cell Lymphoma
Pylorus
Protein Subunits
Helicobacter Infections
Gastritis
Gastric Mucosa
Infection
Peptic Ulcer
Microspheres
MEDLINE
Developing Countries
Stomach
Adenocarcinoma
Costs and Cost Analysis
DNA
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Helicobacter pylori vaccine : From past to future. / Agarwal, Kanishtha; Agarwal, Shvetank.

In: Mayo Clinic Proceedings, Vol. 83, No. 2, 01.01.2008, p. 169-175.

Research output: Contribution to journalReview article

Agarwal, Kanishtha ; Agarwal, Shvetank. / Helicobacter pylori vaccine : From past to future. In: Mayo Clinic Proceedings. 2008 ; Vol. 83, No. 2. pp. 169-175.
@article{113df65fdf004b71841318fd9a6b4935,
title = "Helicobacter pylori vaccine: From past to future",
abstract = "Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma (MALToma), and gastric adenocarcinoma. Infection is usually acquired during childhood and tends to persist unless treated. Because eradication requires treatment with multidrug regimens, prevention of initial infection by a suitable vaccine is attractive. Although immunization with H pylori protein subunits has been encouraging in animals, similar vaccine trials in humans have shown adjuvant-related adverse effects and only moderate effectiveness. Newer immunization approaches (use of DNA, live vectors, bacterial ghosts, and microspheres) are being developed. Several questions about when and whom to vaccinate will need to be appropriately answered, and a cost-effective vaccine production and delivery strategy will have to be useful for developing countries. For this review, we searched MEDLINE using the Medical Subject Heading (MeSH) terms Helicobacter pylori and vaccines for articles in English from 1990 to 2007.",
author = "Kanishtha Agarwal and Shvetank Agarwal",
year = "2008",
month = "1",
day = "1",
doi = "10.4065/83.2.169",
language = "English (US)",
volume = "83",
pages = "169--175",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Helicobacter pylori vaccine

T2 - From past to future

AU - Agarwal, Kanishtha

AU - Agarwal, Shvetank

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma (MALToma), and gastric adenocarcinoma. Infection is usually acquired during childhood and tends to persist unless treated. Because eradication requires treatment with multidrug regimens, prevention of initial infection by a suitable vaccine is attractive. Although immunization with H pylori protein subunits has been encouraging in animals, similar vaccine trials in humans have shown adjuvant-related adverse effects and only moderate effectiveness. Newer immunization approaches (use of DNA, live vectors, bacterial ghosts, and microspheres) are being developed. Several questions about when and whom to vaccinate will need to be appropriately answered, and a cost-effective vaccine production and delivery strategy will have to be useful for developing countries. For this review, we searched MEDLINE using the Medical Subject Heading (MeSH) terms Helicobacter pylori and vaccines for articles in English from 1990 to 2007.

AB - Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma (MALToma), and gastric adenocarcinoma. Infection is usually acquired during childhood and tends to persist unless treated. Because eradication requires treatment with multidrug regimens, prevention of initial infection by a suitable vaccine is attractive. Although immunization with H pylori protein subunits has been encouraging in animals, similar vaccine trials in humans have shown adjuvant-related adverse effects and only moderate effectiveness. Newer immunization approaches (use of DNA, live vectors, bacterial ghosts, and microspheres) are being developed. Several questions about when and whom to vaccinate will need to be appropriately answered, and a cost-effective vaccine production and delivery strategy will have to be useful for developing countries. For this review, we searched MEDLINE using the Medical Subject Heading (MeSH) terms Helicobacter pylori and vaccines for articles in English from 1990 to 2007.

UR - http://www.scopus.com/inward/record.url?scp=39749133744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749133744&partnerID=8YFLogxK

U2 - 10.4065/83.2.169

DO - 10.4065/83.2.169

M3 - Review article

VL - 83

SP - 169

EP - 175

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -